Psoríase pustulosa da infância: relato de caso

Chaves, Yuri Nogueira; Cardoso, Dulceane Natyara; Jorge, Priscila F. Landulfo; Follador, Ivonise; Oliveira, Maria de Fátima Santos Paim de

doi:10.1590/s0365-05962010000600020

Cited by 4 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GPP was first described in 1910 by Von Zumbusch, it is a rare disease, corresponds for less than 5% of psoriasis cases, and considered the most severe subtype of psoriasis [11]. It is characterized by systemic manifestations such as high fever, impairment of general condition, weight loss, muscle weakness, leukocytosis, hypocalcemia, and increased inflammatory evidence, such as erythrocyte sedimentation rate and C-reactive protein, associated with the sudden onset of sterile pustules with 2 and 3 mm over erythematous base that spread to the trunk and limbs [11,12].…”

Section: Discussionmentioning

confidence: 99%

Extensive Deep Venous Thrombosis in a Patient with Interleukin-36 Receptor Antagonist Deficiency (DITRA): A Case Report

Acvd¹,

Fms²,

Pesquero³

et al. 2019

Arch Clin Med Case Rep

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Extensive Deep Venous Thrombosis in a Patient with Interleukin-36 Receptor Antagonist Deficiency (DITRA): A Case Report

Acvd¹,

Fms²,

Pesquero³

et al. 2019

Arch Clin Med Case Rep

View full text Add to dashboard Cite

Inverse Psoriasis Involving Genital Skin Folds: Successful Therapy with Dapsone

Guglielmetti

Conlledo

Bedoya

et al. 2012

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionInverse psoriasis is a rare form of psoriasis that affects between 3% and 7% of the patients with psoriasis. It can comprise genital skin folds as part of genital psoriasis, and it is one of the most commonly seen dermatoses of this area. There are few evidence-based studies about the treatment of intertriginous psoriasis involving genital skin folds.Case PresentationThe authors present a 42-year-old female patient with erythematous plaques in the vulva, groin, and perianal region. The patient had previously received a broad range of topical and systemic therapies that had to be discontinued due to ineffectiveness or side effects. She was treated with 100 mg dapsone daily for 10 months, showing a significant improvement of her cutaneous and mucous lesions. Complete clearance of psoriatic lesions was observed after 4 weeks of treatment. She has remained in remission for up to 2 years, using only topical therapy with tacrolimus 0.1% and calcipotriol.DiscussionGenital psoriasis is a skin disease that causes great discomfort. It is important to include examination of the genital region and to adopt this conduct in daily clinical practice. Research in this field is still poor, making no discrimination between flexural and genital psoriasis, and is based on case series and expert opinion; therefore, empirical recommendations for the treatment of genital psoriasis remain. Dapsone has been shown to be an effective and convenient alternative for the treatment of inverse psoriasis in genital skin folds, which can provide effective control of the disease. Further studies are required to determine the efficacy and safety of current therapies, and to decide whether dapsone therapy should be considered in the management of this form of psoriasis when topical and other systemic agents are not effective.

show abstract

Update on the use of dapsone in dermatology

et al. 2020

View full text Add to dashboard Cite

Dapsone (4,4'‐diaminodiphenylsulfone) is the only remaining sulfone used in anthropoid therapeutics and is commercially available as an oral formulation, an inhaled preparation, and a 5% or 7.5% cream. Dapsone has antimicrobial effects stemming from its sulfonamide‐like ability to inhibit the synthesis of dihydrofolic acid. It also has anti‐inflammatory properties such as inhibiting the production of reactive oxygen species, reducing the effect of eosinophil peroxidase on mast cells and down‐regulating neutrophil‐mediated inflammatory responses. This allows for its use in the treatment of a wide variety of inflammatory and infectious skin conditions. Currently in dermatology, the US Food and Drug Administration (FDA)‐approved indications for dapsone are leprosy, dermatitis herpetiformis, and acne vulgaris. However, it proved itself as an adjunctive therapeutic agent to many other skin disorders. In this review, we discuss existing evidence on the mechanisms of action of dapsone, its FDA‐approved indications, off‐label uses, and side effects.

show abstract

Psoríase pustulosa da infância: relato de caso

Cited by 4 publications

References 13 publications

Extensive Deep Venous Thrombosis in a Patient with Interleukin-36 Receptor Antagonist Deficiency (DITRA): A Case Report

Extensive Deep Venous Thrombosis in a Patient with Interleukin-36 Receptor Antagonist Deficiency (DITRA): A Case Report

Inverse Psoriasis Involving Genital Skin Folds: Successful Therapy with Dapsone

Update on the use of dapsone in dermatology

Contact Info

Product

Resources

About